Clinical Trial

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-28; most recent amendment 2026-05-01.
Trial Details
NCT Number NCT07222553
Lead Sponsor Amgen
Conditions Immunoglobulin G4-related Disease
Enrollment 15 participants
Start Date 2026-07-31
Primary Completion 2031-06-10 (estimated)
Study Completion 2031-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-04